Laserfiche WebLink
HF100 NINTH ENGROSSMENT REVISOR BD 1-10100-9 <br />12.1 system and does not impair the human audio, visual, or mental processes. Nonintoxicating <br />12.2 cannabinoid includes but is not limited to cannabidiol and cannabigerol but does not include <br />12.3 any artificially derived cannabinoid. <br />12.4 Subd. 55. Office. "Office" means the Office of Cannabis Management. <br />12.5 Subd. 56. Outdoor advertisement. "Outdoor advertisement" means an advertisement <br />12.6 that is located outdoors or can be seen or heard by an individual who is outdoors and includes <br />12.7 billboards; advertisements on benches; advertisements at transit stations or transit shelters; <br />12.8 advertisements on the exterior or interior of buses, taxis, light rail transit, or business vehicles; <br />12.9 and print signs that do not meet the requirements in section 342.64, subdivision 2, paragraph <br />12.10 (b), but that are placed or located on the exterior property of a cannabis business. <br />12.11 Subd. 57. Patient. "Patient" means a Minnesota resident who has been diagnosed with <br />12.12 a qualifying medical condition by a health care practitioner and who has met all other <br />12.13 requirements for patients under this chapter to participate in the registry program. <br />12.14 Subd. 58. Patient registry number. "Patient registry number" means a unique <br />12.15 identification number assigned by the Division of Medical Cannabis to a batient enrolled <br />12.16 in the registry program. <br />12.17 Subd. 59. Qualifying medical condition. "Qualifying medical condition" means a <br />12.18 diagnosis of any of the following conditions: <br />12.19 (1) Alzheimer's disease; <br />12.20 (2) autism spectrum disorder that meets the requirements of the fifth edition of the <br />12.21 Diagnostic and Statistical Manual of Mental Disorders published by the American Psychiatric <br />12.22 Association; <br />12.23 (3) cancer, if the underlying condition or treatment produces one or more of the following: <br />12.24 (i) severe or chronic pain; <br />12.25 GO nausea or severe vomiting; or <br />12.26 (iii) cachexia or severe wasting; <br />12.27 (4) chronic motor or vocal tic disorder; <br />12.28 (5) chronic pain; <br />12.29 (6) glaucoma; <br />12.30 (7) human immunodeficiency virus or acquired immune deficiency syndrome; <br />12.31 (8) intractable pain as defined in section 152.125, subdivision 1, paragraph (c); <br />Article 1 Section 1. 12 <br />